pharmaphorum | News & views on pharma and biotech’s evolving …
pharmaphorum is an online publication seeking to educate, inform, engage, & connect pharmaceutical industry leaders to thrive in healthcare’s evolving future.
News | Timely industry updates for pharma and biotech leaders
3 days ago · pharmaphorum’s news coverage updates daily with the latest pharma and biotech stories, from funding and M&A to regulatory approvals and policy shifts.
Life Sciences Industry Report 2025 PART 1 | pharmaphorum
1 day ago · In pharmaphorum’s inaugural Life Sciences Industry Report 2025, delve into the trends that propelled the pharmaceutical industry along in 2024.
About pharmaphorum
Jan 3, 2025 · pharmaphorum.com is a leading online destination for healthcare and pharmaceutical industry news, insight, and debate – as is its associated digital magazine Deep Dive. www.pharmaphorum.com
FDA issues first guidance on AI in medicine development
3 days ago · The FDA has responded to the increasing use of artificial intelligence (AI) in the discovery and development of drugs and biologics by publishing its first provisional guidance on the technology's ...
Novo Nordisk asks FDA not to allow GLP-1 compounding
5 days ago · Novo joins Lilly in asking FDA for ban on GLP-1 compounding. Novo Nordisk has asked the FDA to stop compounding pharmacies making cheaper versions of its semaglutide-based therapies for obesity ...
The biopharma outlook for 2025: Opportunities and challenges
2 days ago · With the Federal Reserve poised to implement interest rate cuts (albeit fewer than earlier forecasts assumed) and FTC leadership turnover anticipated, there may be broader shifts in how capital is ...
pharmaphorum - The Deep Dive Digital Magazine has fresh …
Feb 28, 2024 · Digital Health 2023. 29-11-2023 Deep Dive – Digital Health 2023 features interviews, analysis, and commentary from pharmaphorum, Lumanity, AXON, Viseven, Research Partnership, PurpleLeaf Strategy, M3, and more
Cassava’s Alzheimer’s drug nears P3 readout, but SEC scandal …
4 days ago · Cassava Sciences is nearing a Phase 3 readout for its Alzheimer's drug, lecanemab, despite facing a scandal involving the SEC. Learn more about the latest updates on donanemab and the company's ...
Deep Dive | A bimonthly magazine for in-depth pharma stories
pharmaphorum presents a bimonthly Deep Dive magazine with extended, visually appealing features on R&D, patients, market access, digital health, and more.